The funding and seasoned leadership give iRiva the resources and expertise to accelerate development of neuromodulation therapies, a high‑growth segment of med‑tech, while underscoring investor confidence in accelerator‑sourced startups. Successful commercialization could address unmet needs for chronic disease management and generate significant market upside.
Comments
Want to join the conversation?
Loading comments...